CN116457344B - 低分子量蛋白质降解剂及其应用 - Google Patents

低分子量蛋白质降解剂及其应用

Info

Publication number
CN116457344B
CN116457344B CN202180067832.3A CN202180067832A CN116457344B CN 116457344 B CN116457344 B CN 116457344B CN 202180067832 A CN202180067832 A CN 202180067832A CN 116457344 B CN116457344 B CN 116457344B
Authority
CN
China
Prior art keywords
compound
alkyl
cancer
methyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180067832.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN116457344A (zh
Inventor
S·科唐
N·迪金森
K·卡扎诺夫斯卡
K·奥德兹维尔
R·普鲁塔
M·瓦尔扎克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Captor Therapeutics SA
Original Assignee
Captor Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Captor Therapeutics SA filed Critical Captor Therapeutics SA
Publication of CN116457344A publication Critical patent/CN116457344A/zh
Application granted granted Critical
Publication of CN116457344B publication Critical patent/CN116457344B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180067832.3A 2020-08-03 2021-08-03 低分子量蛋白质降解剂及其应用 Active CN116457344B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLPCT/PL2020/000066 2020-08-03
PL2020000066 2020-08-03
PCT/EP2021/071694 WO2022029138A1 (en) 2020-08-03 2021-08-03 Low molecular weight protein degraders and their applications

Publications (2)

Publication Number Publication Date
CN116457344A CN116457344A (zh) 2023-07-18
CN116457344B true CN116457344B (zh) 2026-05-12

Family

ID=72193535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180067832.3A Active CN116457344B (zh) 2020-08-03 2021-08-03 低分子量蛋白质降解剂及其应用

Country Status (11)

Country Link
US (1) US20240294489A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188373A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023541522A (cg-RX-API-DMAC7.html)
KR (1) KR20230048373A (cg-RX-API-DMAC7.html)
CN (1) CN116457344B (cg-RX-API-DMAC7.html)
AU (1) AU2021319847A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001956A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186919A1 (cg-RX-API-DMAC7.html)
IL (1) IL300308A (cg-RX-API-DMAC7.html)
MX (1) MX2023001401A (cg-RX-API-DMAC7.html)
WO (1) WO2022029138A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117440948A (zh) * 2021-06-28 2024-01-23 成都分迪药业有限公司 酰胺类化合物及其用途
CN114933584B (zh) * 2021-08-09 2022-12-27 上海贵之言医药科技有限公司 一种二氢-2h-异吲哚酯类化合物
CN116082301A (zh) * 2021-11-05 2023-05-09 上海美志医药科技有限公司 具有降解gspt1活性的化合物及其应用
WO2023085785A1 (ko) * 2021-11-09 2023-05-19 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
AU2022405474B2 (en) * 2021-12-08 2026-08-13 Gluetacs Therapeutics (Shanghai) Co., Ltd. E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) * 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド CK1αおよびDUAL CK1α/GSPT1分解化合物
WO2024096753A1 (en) 2022-11-02 2024-05-10 Captor Therapeutics S.A. Nek7 degraders and methods of use thereof
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102112463A (zh) * 2008-05-30 2011-06-29 细胞基因公司 5-取代的异二氢吲哚化合物
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2019241274A1 (en) * 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
AU2007290407A1 (en) * 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US8927725B2 (en) * 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
IL319363A (en) * 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
JP7258009B2 (ja) 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CA3075813A1 (en) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor sall4 and uses thereof
EA202191833A1 (ru) * 2018-12-31 2021-10-11 Селджин Корпорейшн Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102112463A (zh) * 2008-05-30 2011-06-29 细胞基因公司 5-取代的异二氢吲哚化合物
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2019241274A1 (en) * 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN REG数据库 .STN REG数据库 .2020, *

Also Published As

Publication number Publication date
CN116457344A (zh) 2023-07-18
MX2023001401A (es) 2023-05-03
JP2023541522A (ja) 2023-10-03
CA3186919A1 (en) 2022-02-10
AU2021319847A1 (en) 2023-03-02
EP4188373A1 (en) 2023-06-07
US20240294489A1 (en) 2024-09-05
KR20230048373A (ko) 2023-04-11
IL300308A (en) 2023-04-01
BR112023001956A2 (pt) 2023-02-28
WO2022029138A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CN116457344A (zh) 低分子量蛋白质降解剂及其应用
US11859014B2 (en) Peptidomimetics for the treatment of Norovirus infection
TWI851542B (zh) Shp2之八氫環戊烷并[c]吡咯別構抑制劑
AU2015276537B2 (en) Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
CN115989223B (zh) 使用CCR8抑制剂靶向Tregs的方法和组合物
TW202341983A (zh) 用於降解突變kras蛋白之化合物及其應用
JP5886411B2 (ja) 新規のピリミジン誘導体
WO2020160198A1 (en) Compounds and uses thereof
US20040152759A1 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
KR20120055571A (ko) 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸
US20220002291A1 (en) Proteolysis-targeting chimeras
JP6314128B2 (ja) 新たなアルキル化剤
CN113614095A (zh) 作为精氨酸酶抑制剂的烷基硼酸类化合物
RU2632199C2 (ru) Функционализированные производные тиеноиндола для лечения ракового заболевания
JPWO2016039398A1 (ja) 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
CN115003650A (zh) 二取代金刚烷基衍生物、其药学上可接受的盐及包含其作为有效成分的用于抑制癌生长的药物组合物
CN114390924A (zh) 用于蛋白质降解的化合物、组合物和方法
CN118852335A (zh) 噻二唑烷酮衍生物及其制备方法和应用
EP3969450B1 (en) Quinazoline-2,4-dione derivatives as parp inhibitors
CN103450062B (zh) 一种治疗肿瘤的双靶点药物化合物及其制备方法和用途
CN121045188A (zh) 1,2-二氢吡咯并[1,2-a]吡嗪-3(4H)-酮衍生物及其用途
HK40062378B (en) Quinazoline-2,4-dione derivatives as parp inhibitors
HK40062378A (en) Quinazoline-2,4-dione derivatives as parp inhibitors
HK1120406A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant